Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
02496 友芝友生物-B
Listing Date2023/09/25
Listing Price16.000
  • 7.450 0.000 (0.000%)    Sink Below Listing Price
  • 15-min delayed, last update: 27/05/2024 17:59
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    30 lot
  • One Lot Success Rate

Wuhan YZY Biopharma Co. is a biotechnology company dedicated to developing bispecific antibody (BsAb)-based therapies to treat cancer-associated complications, cancer and agerelated ophthalmologic diseases.


The Group have designed and developed a pipeline of seven clinical-stage drug candidates, including its Core Product M701, which it is currently conducting a Phase II clinical trial in treating malignant ascites (MA) and a Phase Ib/II clinical trial in treating malignant pleural effusion (MPE), and six other drug candidates at various clinical stages.


The Group is currently developing M701 primarily as a palliative care for MA and MPE, which are severe complications of cancer where fluids build up in the abdominal or chest cavity of cancer patients, and not for the treatment for cancer itself.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot200
No. of Offer Shares11.00M H shares
No. of International Offer Shares9.90M H shares
No. of HK Offer Shares1.10M H shares
Offer Price$16.00 - $20.00
Stock Code2496
Sponsor(s)China Securities (International) Corporate Finance Company Limited
Underwriter(s)China Securities (International) Corporate Finance Company Limited, Guotai Junan Securities (Hong Kong) Limited, CCB International Capital Limited, BOCI Asia Limited, TFI Securities and Futures Limited, China Galaxy International Securities (Hong Kong) Co., Limited, Livermore Holdings Limited, Futu Securities International (Hong Kong) Limited
Application PeriodSep 13 (Wed) - noon, Sep 18 (Mon)
Price Determination DateSep 18 (Mon)
Result Announcement DateOn or before Sep 22 (Fri)
Result Announcement DateOn or before Sep 22 (Fri)
Result Announcement DateOn or before Sep 22 (Fri)
Dealings in Shares commence onSep 25, 2023. (Mon)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$16.00 - $20.00
Capitalization3.09B - 3.86B
NAV / share ($)$1.23 - $1.45 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 18.00, the net proceeds raised would be HKD 142.40M, of which
80% : For planned clinical trials, preparation for registration filings, and planned commercial launch of Core Product M701
12% : For planned clinical trials of Y101D
8% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.